User profiles for Frank J. Accurso
 | Frank AccursoProfessor emeritus pediatrics, university of Colorado school of medicine Verified email at childrenscolorado.org Cited by 23210 |
Early pulmonary inflammation in infants with cystic fibrosis.
…, T Bost, J Martinez, FJ Accurso… - American journal of …, 1995 - atsjournals.org
The mechanisms underlying the initiation of lung disease and early respiratory morbidity in
cystic fibrosis (CF) are poorly understood. By identifying infants with CF through a statewide …
cystic fibrosis (CF) are poorly understood. By identifying infants with CF through a statewide …
Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report
PM Farrell, BJ Rosenstein, TB White, FJ Accurso… - The Journal of …, 2008 - Elsevier
Newborn screening (NBS) for cystic fibrosis (CF) is increasingly being implemented and is
soon likely to be in use throughout the United States, because early detection permits access …
soon likely to be in use throughout the United States, because early detection permits access …
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial
…, DA Cibene, S Coquillette, AY Fieberg, FJ Accurso… - Jama, 2003 - jamanetwork.com
ContextTreatment strategies for cystic fibrosis (CF) lung disease include antibiotics, mucolytics,
and anti-inflammatory therapies. Increasing evidence suggests that macrolide antibiotics …
and anti-inflammatory therapies. Increasing evidence suggests that macrolide antibiotics …
[HTML][HTML] Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
FJ Accurso, SM Rowe, JP Clancy… - … England Journal of …, 2010 - Mass Medical Soc
Background A new approach in the treatment of cystic fibrosis involves improving the function
of mutant cystic fibrosis transmembrane conductance regulator (CFTR). VX-770, a CFTR …
of mutant cystic fibrosis transmembrane conductance regulator (CFTR). VX-770, a CFTR …
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
JP Clancy, SM Rowe, FJ Accurso, ML Aitken, RS Amin… - Thorax, 2012 - thorax.bmj.com
Background VX-809, a cystic fibrosis transmembrane conductance regulator (CFTR) modulator,
has been shown to increase the cell surface density of functional F508del-CFTR in vitro. …
has been shown to increase the cell surface density of functional F508del-CFTR in vitro. …
[HTML][HTML] Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis
…, KK Brown, JD Brain, FJ Accurso… - The Journal of …, 2002 - Am Soc Clin Investig
Cystic fibrosis is characterized by an early and sustained influx of inflammatory cells into the
airways and by release of proteases. Resolution of inflammation is normally associated with …
airways and by release of proteases. Resolution of inflammation is normally associated with …
Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis
…, TB White, PM Farrell, BC Marshall, FJ Accurso - The Journal of …, 2009 - Elsevier
Newborn screening for cystic fibrosis (CF) offers the opportunity for early medical and
nutritional intervention that can lead to improved outcomes. Management of the asymptomatic …
nutritional intervention that can lead to improved outcomes. Management of the asymptomatic …
Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis
…, H Kaess, RR Deterding, FJ Accurso… - Proceedings of the …, 2007 - National Acad Sciences
Culture of bronchoalveolar lavage fluid (BALF) is the gold standard for detection of pathogens
in the lower airways in cystic fibrosis (CF). However, current culture results do not explain …
in the lower airways in cystic fibrosis (CF). However, current culture results do not explain …
Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway
In cystic fibrosis, dysregulated neutrophilic inflammation and chronic infection lead to
progressive destruction of the airways. The underlying mechanisms have remained unclear. …
progressive destruction of the airways. The underlying mechanisms have remained unclear. …
Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
…, MW Konstan, K De Boeck, FJ Accurso… - The Lancet …, 2014 - thelancet.com
Background Ataluren was developed to restore functional protein production in genetic disorders
caused by nonsense mutations, which are the cause of cystic fibrosis in 10% of patients…
caused by nonsense mutations, which are the cause of cystic fibrosis in 10% of patients…